Innocrin Pharmaceuticals' Other Investors

Innocrin Pharmaceuticals raised a round of funding on , . Investors include Astellas Venture Management.

Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally…

Articles about Innocrin Pharmaceuticals' Other Investors: